All In Biotech

NDA 213645 · Baxter Hlthcare Corp

Daptomycin In 0.9% Sodium Chloride

Daptomycin · Intravenous · Lipopeptide Antibacterial

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Jan 25, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

94

20 Phase 3, 4 recruiting

FAERS reports

9,505

8,808 serious, 1,286 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 24, 2026.

Daptomycin in Sodium Chloride Injection is a lipopeptide antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) for whom appropriate dosing can be achieved ( 1.1 ) and, • Staphylococcus aureus bloodstream infections (bacteremia), in adult patients for whom appropriate dosing can be achieved, including those with right-sided infective endocarditis, ( 1.2 ) • Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age) for whom appropriate dosing can be achieved. ( 1.3 ) Limitations of Use • Daptomycin in Sodium Chloride Injection is not indicated for the treatment of pneumonia. ( 1.4 ) • Daptomycin in Sodium Chloride Injection is not indicated for the treatment of left-sided infective endocarditis due to S. aureus. ( 1.4 ) • Daptomycin in Sodium Chloride Injection is not recommended in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs. ( 1.4 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Daptomycin in Sodium Chloride Injection and other antibacterial drugs, Daptomycin in Sodium Chloride Injection should be used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 ) 1.1 Complicated Skin and Skin Structure Infections (cSSSI) Daptomycin in Sodium Chloride Injection is indicated for the treatment of adult and pediatric patients (1 to 17 years of age) for whom appropriate dosing can be achieved, with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the...

Mechanism: Daptomycin is an antibacterial drug [see Clinical Pharmacology (12.4) ] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 27, 2023 Supplement 1 · Efficacy LabelLetter
  • Jan 25, 2022 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
5 products under this application
  • DAPTOMYCIN IN 0.9% SODIUM CHLORIDE · DAPTOMYCIN 700MG/100ML (7MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • DAPTOMYCIN IN 0.9% SODIUM CHLORIDE · DAPTOMYCIN 350MG/50ML (7MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • DAPTOMYCIN IN 0.9% SODIUM CHLORIDE · DAPTOMYCIN 1GM/100ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • DAPTOMYCIN IN 0.9% SODIUM CHLORIDE · DAPTOMYCIN 500MG/50ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • DAPZURA RT · DAPTOMYCIN 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Daptomycin" as an intervention, any sponsor and status, largest first.

All 94 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective768
  • off label use703
  • acute kidney injury628
  • eosinophilic pneumonia489
  • pyrexia481
  • rhabdomyolysis389
  • eosinophilia387
  • drug reaction with eosinophilia and systemic symptoms344
  • blood creatine phosphokinase increased329
  • product use in unapproved indication321
  • neutropenia302
  • thrombocytopenia288

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200410
200521
200622
200723
200831
200978
201067
201187
2012121
2013117
2014128
2015319
2016237
2017307
2018595
2019491
2020665
2021836
2022899
20231,100
20241,108
20251,183
20261,060

Recalls

2 FDA enforcement reports for this application.

  • Aug 6, 2026 · Class II · Ongoing

    CGMP Deviations

  • Aug 6, 2026 · Class II · Ongoing

    CGMP Deviations

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 153 on PubMed

Sponsor: Baxter Hlthcare Corp · Also marketed as Dapzura Rt

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.